abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

這頁面沒有繁體中文版本,現以English顯示

文章

2003年3月25日

作者:
Sarah Boseley, Guardian [UK]

Investors pressure drug firms on pricing

Multinationals urged to allow developing countries to sidestep patents on life-saving treatments - Drug companies were given a stark warning yesterday that blocking access to life-saving drugs at affordable prices by poor countries could undermine public confidence in them and damage the value of their shares in the long term. The unprecedented pressure on the multinationals comes from major City institutions with investments of more than £600bn and backed by well-known names such as Jupiter, Schroders and Legal and General Investment Management.